As Gilead Sciences INC (GILD) Share Value Rose, Finemark National Bank & Trust Raised Its Stake

May 22, 2018 - By wolcottdaily

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It worsened, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. 76,176 are owned by Meeder Asset Mgmt. Two Sigma Limited reported 45,643 shares or 0.09% of all its holdings. Hawaii-based Bank & Trust Of Hawaii has invested 0.25% in Gilead Sciences, Inc. (NASDAQ:GILD). Orrstown Financial holds 0% or 35 shares in its portfolio. Cincinnati Insurance stated it has 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD). Walter & Keenan Consulting Mi Adv owns 6,170 shares or 0.19% of their US portfolio. Moreover, Empirical Finance Services Limited has 0.07% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Farmers Merchants accumulated 15,784 shares or 0.08% of the stock. Warren Averett Asset Mngmt Ltd holds 0.05% or 5,083 shares. Philadelphia Trust Communication holds 21,980 shares or 0.12% of its portfolio. National Pension Service has 0.38% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Ajo Limited Partnership owns 1.28 million shares or 0.4% of their US portfolio. Jacobs Co Ca reported 0.36% in Gilead Sciences, Inc. (NASDAQ:GILD). Massachusetts Financial Ma has 7,496 shares. State Of New Jersey Common Pension Fund D, New Jersey-based fund reported 1.57M shares.

Since January 2, 2018, it had 0 insider buys, and 22 insider sales for $44.80 million activity. $3.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C. Shares for $2.37 million were sold by Alton Gregg H. Cogan John Francis also sold $437,588 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. Washington Robin L sold $401,566 worth of stock or 5,000 shares. $4.68M worth of stock was sold by WILSON GAYLE E on Friday, February 9.

Finemark National Bank & Trust increased its stake in Gilead Sciences Inc (GILD) by 341.82% based on its latest 2017Q4 regulatory filing with the SEC. Finemark National Bank & Trust bought 45,277 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 58,523 shares of the health care company at the end of 2017Q4, valued at $4.19M, up from 13,246 at the end of the previous reported quarter. Finemark National Bank & Trust who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $87.94 billion market cap company. The stock decreased 0.57% or $0.39 during the last trading session, reaching $67.63. About 5.00 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 22, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” on May 16, 2018, also Seekingalpha.com with their article: “Gilead: Where’s The Next Catalyst?” published on May 18, 2018, Seekingalpha.com published: “Gilead: What A Disaster” on May 08, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Should The FDA Be Shaming Drug Companies? Financial Advisors’ Daily Digest” published on May 21, 2018 as well as Seekingalpha.com‘s news article titled: “Kite Pharma continues buildout for cell therapy manufacture” with publication date: May 15, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 14 analysts covering Gilead Sciences (NASDAQ:GILD), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. Gilead Sciences had 24 analyst reports since November 30, 2017 according to SRatingsIntel. The rating was maintained by Wells Fargo on Monday, January 29 with “Buy”. As per Thursday, December 21, the company rating was maintained by Oppenheimer. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Overweight” rating given on Tuesday, March 6 by Barclays Capital. The rating was maintained by Credit Suisse with “Hold” on Wednesday, January 3. The firm has “Hold” rating by Leerink Swann given on Wednesday, May 2. Mizuho maintained it with “Buy” rating and $83.0 target in Monday, February 5 report. Barclays Capital maintained it with “Overweight” rating and $90 target in Wednesday, May 2 report. On Wednesday, February 7 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Thursday, February 22 by Leerink Swann. The firm has “Buy” rating given on Wednesday, February 7 by Cowen & Co.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.